Approvals· August 10, 2026 · 14 min read
177Lu-Edotreotide (ITM-11) for GEP-NET: COMPETE Phase 3 Data and Lutathera Access
By Ran Chen#Radiolabeled Therapy#Oncology#FDA Approval
177Lu-edotreotide (ITM-11) NDA review, COMPETE Phase 3 GEP-NET evidence, no-carrier-added lutetium-177 formulation, and quarterly dosing.